☆ 4.8 Editorial Material

Impression, Sunset

CIRCULATION (2013)

期刊

CIRCULATION

卷 127, 期 10, 页码 1098-1100

出版社

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/CIRCULATIONAHA.113.001460

关键词

Editorials; pulmonary hypertension

类别

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Pharmacology & Pharmacy

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis

Ruihua Zhang, Tengfei Li, Yueming Shao, Wei Bai, Xiaoyu Wen

Summary: This study systematically reviewed and meta-analyzed the therapeutic effect of PAH agents on POPH. The results showed that PAH agents can improve cardiopulmonary hemodynamics and cardiac function in patients with POPH, especially in patients with moderate to severe POPH.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Review Critical Care Medicine

Pulmonary Hypertension: A Contemporary Review

Shelsey Johnson, Natascha Sommer, Katherine Cox-Flaherty, Norbert Weissmann, Corey E. Ventetuolo, Bradley A. Maron

Summary: This article summarizes the major advances in pulmonary arterial hypertension, pulmonary hypertension associated with lung disease, and chronic thromboembolic PH. It highlights key findings in basic, translational, and clinical research, and discusses the latest progress in translational pulmonary vascular biology and the management of PH.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Article Critical Care Medicine

Lung Transplantation for Pulmonary Arterial Hypertension

Nicholas A. Kolaitis

Summary: Lung transplantation is a unique and effective treatment option for patients with end-stage pulmonary arterial hypertension. However, these patients face various challenges and inequities in the organ allocation process, resulting in less favorable long-term outcomes.

CHEST (2023)

添加到收藏夹

Article Medicine, General & Internal

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension in Greece: Data from the Hellenic Pulmonary Hypertension Registry

Panagiotis Karyofyllis, Eftychia Demerouti, George Giannakoulas, Anastasia Anthi, Alexandra Arvanitaki, George Athanassopoulos, Christos Feloukidis, Ioannis Iakovou, Theodora Kostelidou, Ioanna Mitrouska, Sophia-Anastasia Mouratoglou, Stylianos E. Orfanos, Christos Pappas, Georgia Pitsiou, Eleftheria-Garyfallia Tsetika, Dimitrios Tsiapras, Vassilios Voudris, Athanassios Manginas

Summary: This study analyzed data from 180 BPA procedures in CTEPH patients and found that the procedure significantly improved mean pulmonary arterial pressure, pulmonary vascular resistance, and NT-proBNP levels, with a modest improvement in cardiac index. Although there were some complications associated with BPA, the overall survival rate was high, indicating that BPA is a promising therapeutic option for CTEPH patients in Greece.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Novel hub genes associated with pulmonary artery remodeling in pulmonary hypertension

Rubin Tan, Qiang You, Dongdong Yu, Chushu Xiao, Joseph Adu-Amankwaah, Jie Cui, Ting Zhang

Summary: In this study, we identified novel common hub genes involved in pulmonary artery remodeling in different PH groups through the analysis of gene expression data. We verified the top 10 candidate genes through animal model validation. This study provides new target genes for further research on the mechanisms and treatment of PH.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness and Safety of Balloon Pulmonary Angioplasty for the Treatment of Patients with Persistent Pulmonary Hypertension after Pulmonary Endarterectomy

Nicolas Maneiro M. Melon, Maite Velazquez Martin, Sergio Huertas Nieto, Agustin Albarran Gonzalez-Trevilla, Fernando Sarnago Cebada, Alejandro Cruz Utrilla, Williams Hinojosa Camargo, Ricardo Aguilar Colindres, Maria Melendo Viu, Maria Jesus Lopez Gude, Rafael Morales Ruiz, Marta Perez Nunez, Fernando Arribas Ynsaurriaga, Pilar Escribano Subias

Summary: This study retrospectively collected data from 14 patients with persistent pulmonary hypertension (PH) after pulmonary endarterectomy (PEA) who were treated with balloon pulmonary angioplasty (BPA). The results showed that BPA effectively reduced pulmonary arterial pressure and pulmonary vascular resistance, and improved the clinical status of patients. Severe BPA-related complications were rare and no perioperative deaths were observed.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pulmonary-to-Systemic Arterial Shunt to Treat Children With Severe Pulmonary Hypertension

R. Mark Grady, Matthew W. Canter, Fei Wan, Anton A. Shmalts, Ryan D. Coleman, Maurice Beghetti, Rolf M. F. Berger, Maria J. del Cerro Marin, Scott E. Fletcher, Russel Hirsch, Tilman H. Umpl, D. Dunbar Ivy, Edward C. Kirkpatrick, Thomas J. Kulik, Marilyne Levy, Shahin Moledina, Delphine Yung, Pirooz Eghtesady, Damien Bonnet

Summary: Pulmonary-to-systemic arterial shunt surgery provides significant clinical improvement for children with severe PH, with high survival rates after discharge, while children at high risk in-hospital are not suitable candidates for the procedure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pulmonary artery denervation for pulmonary arterial hypertension *

Andrew Constantine, Konstantinos Dimopoulos

Summary: Pulmonary artery denervation is a novel intervention aimed at reducing sympathetic activity in the pulmonary circulation for the treatment of pulmonary arterial hypertension. Despite some positive effects shown in pre-clinical studies and initial clinical trials, the technique's scope in current practice remains limited due to the lack of well-designed, large-scale, international randomized controlled clinical trials.

TRENDS IN CARDIOVASCULAR MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism

Gudula J. A. M. Boon, Yvonne M. Ende-Verhaar, Ludo F. M. Beenen, Johan Coolen, Marion Delcroix, Marek Golebiowski, Menno Huisman, Albert T. A. Mairuhu, Lilian J. Meijboom, Saskia Middeldorp, Piotr Pruszczyk, Cornelis J. van Rooden, Anton Vonk Noordegraaf, Lucia J. M. Kroft, Frederikus A. Klok

Summary: The study found that the presence of three or more predefined radiological predictors in patients with acute PE was highly specific for predicting future CTEPH diagnosis, comparable to overall expert judgment, with the latter showing higher sensitivity. Dedicated CTPA reading for signs of CTEPH may help in early detection of CTEPH after PE, although not detecting all cases in the cohort.

EUROPEAN RADIOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review of the Most Updated Literature

Eleonora Faccioli, Vincenzo Verzeletti, Martina Perazzolo Marra, Annalisa Boscolo, Marco Schiavon, Paolo Navalesi, Federico Rea, Andrea Dell'Amore

Summary: This systematic review focuses on the pre-operative evaluation, intra-operative procedure, and post-operative results of pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study found that PEA is an acceptable treatment option with satisfactory short- and long-term outcomes in highly experienced CTEPH centers. The decision to perform PEA should be made by a multidisciplinary team consisting of surgeons, pulmonologists, and radiologists.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Review Immunology

Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening

Shao-Fei Liu, Netra Nambiar Veetil, Qiuhua Li, Mariya M. M. Kucherenko, Christoph Knosalla, Wolfgang M. M. Kuebler

Summary: Pulmonary hypertension is a progressive disease caused by inflammation, which leads to pulmonary arterial stiffness and vascular remodeling, driving the progression of the disease.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Circulating Blood-Based Biomarkers in Pulmonary Hypertension

Marta Banaszkiewicz, Aleksandra Gasecka, Szymon Darocha, Michal Florczyk, Arkadiusz Pietrasik, Piotr Kedzierski, Michal Pilka, Adam Torbicki, Marcin Kurzyna

Summary: Pulmonary hypertension is a serious hemodynamic condition that can lead to right heart failure and death if not properly treated. The prognosis of pulmonary hypertension depends on various factors, and biomarkers provide information about disease severity, treatment response, and prognosis. However, due to the complexity of the condition, a single biomarker is not sufficient for evaluating different types of pulmonary hypertension patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Risk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy

Stefano Ghio, Catherine Klersy, Angelo Corsico, Sofia Lucia Gamba, Cristian Monterosso, Joice Masiglat, Ermelinda Borrelli, Laura Scelsi, Alessandra Greco, Davide Piloni, Luigi Oltrona Visconti, Andrea Maria D'Armini

Summary: This study demonstrated that including parameters such as CPA and PaO2 in addition to standard hemodynamic parameters can improve risk stratification in patients with residual PH after PEA, leading to more accurate prognostic assessment.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances

Bradley A. Maron, Steven H. Abman, C. Greg Elliott, Robert P. Frantz, Rachel K. Hopper, Evelyn M. Horn, Mark R. Nicolls, Oksana A. Shlobin, Sanjiv J. Shah, Gabor Kovacs, Horst Olschewski, Erika B. Rosenzweig

Summary: The diagnosis and management of pulmonary arterial hypertension have seen advances in early diagnosis, multiple pharmacotherapeutics, and new risk factors becoming focal points. Developmental biology may be useful in predicting incident PAH.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy

Ryosuke Ito, Jun Yamashita, Yuichi Sasaki, Sayo Ikeda, Shun Suzuki, Naotaka Murata, Hitoshi Ogino, Taishiro Chikamori

Summary: The study compared the outcomes of balloon pulmonary angioplasty (BPA) between patients with residual pulmonary hypertension after pulmonary endarterectomy (PEA) and those with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The results showed no significant differences in BPA outcomes between the two groups, but the PH after PEA group had a higher rate of severe hemoptysis as a complication.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension Insights From the Randomized Controlled Study With Selexipag (TRACE)

Luke S. Howard, Stephan Rosenkranz, Robert P. Frantz, Anna R. Hemnes, Thomas P. Fister, Shu-Fang Hsu Schmitz, Hall Skara, Marc Humbert, Ioana R. Preston

Summary: The study investigated the changes in daily life physical activity (DLPA) in pulmonary arterial hypertension (PAH) patients receiving selexipag or placebo using actigraphy. The results showed no statistically significant differences in NSPA, MVPA, and daily steps between the treatment and placebo groups. This study provides high-quality actigraphy data and insights into DLPA in PAH, which may guide future research design.

CHEST (2023)

添加到收藏夹

Article Respiratory System

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper, Roberto Badagliacca, Rolf M. F. Berger, Margarita Brida, Jorn Carlsen, Andrew J. S. Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S. Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G. Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M. Olsson, Joanna Pepke-Zaba, Jennifer K. Quint, Goran Radegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, Mark Toshner, Jean Luc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz

EUROPEAN RESPIRATORY JOURNAL (2023)

添加到收藏夹

Article Respiratory System

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Janethe de Oliveira Pena, David B. Badesch

Summary: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significant reduction in pulmonary vascular resistance. This study reports the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension, showing that sotatercept has good safety and efficacy in patients with pulmonary arterial hypertension.

EUROPEAN RESPIRATORY JOURNAL (2023)

添加到收藏夹

Editorial Material Respiratory System

PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease

Jason Weatherald, Marc Humbert

RESPIROLOGY (2023)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Stephan Rosenkranz, Marion Delcroix, George Giannakoulas, Marius M. Hoeper, Gabor Kovacs, Marc Humbert

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Respiratory System

Cytokines as prognostic biomarkers in pulmonary arterial hypertension

Athenais Boucly, Ly Tu, Christophe Guignabert, Christopher Rhodes, Pascal De Groote, Gregoire Prevot, Emmanuel Bergot, Arnaud Bourdin, Antoine Beurnier, Anne Roche, Mitja Jevnikar, Xavier Jais, David Montani, Martin R. Wilkins, Marc Humbert, Olivier Sitbon, Laurent Savale

Summary: In this study, a three-biomarker panel consisting of beta-NGF, CXCL9, and TRAIL in serum was identified to be independently associated with prognosis in patients with PAH. These biomarkers showed stronger prognostic value for survival compared to conventional non-invasive variables such as NYHA Functional Class, 6-min walk distance, and BNP/NT-proBNP. The results were validated in an independent external validation cohort.

EUROPEAN RESPIRATORY JOURNAL (2023)

添加到收藏夹

Article Respiratory System

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam

Summary: AV-101, a dry powder inhaled formulation of imatinib, was well tolerated in healthy adults and significantly reduced the systemic exposure of imatinib compared with oral imatinib. An ongoing study will evaluate the safety, tolerability, and clinical benefit of AV-101 for pulmonary arterial hypertension.

ERJ OPEN RESEARCH (2023)

添加到收藏夹

Editorial Material Critical Care Medicine

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension

Jason Weatherald, Umberto Zanini, Marc Humbert

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

The European reference network on rare lung diseases (ERN-LUNG) ambition to offer better lung health for all

Marc Humbert, Thomas Wagner

PRESSE MEDICALE (2023)

添加到收藏夹

Review Critical Care Medicine

Management of Acutely Decompensated Pulmonary Hypertension

Laurent Savale, Mithum Kularatne, Anne Roche, Jeremie Pichon, Audrey Baron, Athenais Boucly, Olivier Sitbon, Marc Humbert

Summary: Pulmonary arterial hypertension is a life-threatening condition characterized by increased pulmonary vascular resistance and right heart dysfunction. Admission to the intensive care unit with acute decompensated right heart failure is associated with a high risk of organ dysfunction and death. Various organ systems can be affected, and prompt identification and management of triggering events are crucial. Treatment goals include reversing ventriculo-arterial decoupling and reducing right ventricular afterload to prevent the progression of right heart failure. In cases of refractory dysfunction, lung transplantation and mechanical circulatory support may be considered.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Review Critical Care Medicine

Updated Hemodynamic Definition and Classification of Pulmonary Hypertension

Benoit Lechartier, Mithum Kularatne, Xavier Jais, Marc Humbert, David Montani

Summary: Pulmonary hypertension (PH) is a group of diseases characterized by abnormally elevated pulmonary arterial pressures diagnosed on right heart catheterization. The 2022 ESC/ERS Guidelines provide a new hemodynamic definition for PH, lowering the threshold of mean pulmonary artery pressure (mPAP) to 20 mm Hg. Precapillary PH is now defined as mPAP >20 mm Hg with normal pulmonary artery wedge pressure (<15 mm Hg) and increased pulmonary vascular resistance (>2 Wood Units). The guidelines also introduce a revised clinical classification of PH based on underlying pathophysiology.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Review Critical Care Medicine

Management of Pulmonary Arterial Hypertension

Jason Weatherald, Rhea A. Varughese, Jonathan Liu, Marc Humbert

Summary: Pulmonary arterial hypertension (PAH) is a rare disease characterized by progressive pulmonary arterial remodeling, increased resistance, right ventricular dysfunction, and reduced survival. Current approved therapies for PAH target nitric oxide, endothelin-1, and prostacyclin pathways. Treatment includes oral medications for low- and intermediate-risk patients, with consideration of triple therapy for high-risk patients. Combination therapy may not be suitable for PAH patients with cardiopulmonary comorbidities. Supportive and adjunctive treatments are also important, and lung transplantation may be considered for patients who do not respond to medical care. Additional therapies are needed to improve outcomes in PAH.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Review Respiratory System

Pulmonary hypertension associated with diazoxide: the SUR1 paradox

David Montani, Fabrice Antigny, Etienne-Marie Jutant, Marie-Camille Chaumais, Helene Le Ribeuz, Julien Grynblat, Charles Khouri, Marc Humbert

Summary: The ATP-sensitive potassium channels and their regulatory subunits, SUR1 and SUR2, have a significant role in the pathophysiology of pulmonary hypertension. Loss-of-function variants in ABCC8 gene, which encodes for SUR1, are associated with heritable pulmonary arterial hypertension, while activation of SUR1 and SUR2 leads to relaxation of pulmonary arteries and reduces cell proliferation and migration. Diazoxide, an activator of SUR1, has shown potential as a therapeutic option for pulmonary hypertension. However, there are contradictory reports of diazoxide-induced pulmonary hypertension in infants.

ERJ OPEN RESEARCH (2023)

添加到收藏夹

Article Respiratory System

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma

Jonathan Corren, Constance H. Katelaris, Mario Castro, Jorge F. Maspero, Marc Humbert, David M. G. Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe

Summary: For patients with uncontrolled, moderate-to-severe asthma and elevation of at least one type 2 biomarker, long-term treatment with dupilumab can lead to sustained reduction in exacerbation rates and improvements in lung function and asthma control, regardless of exacerbation history.

ERJ OPEN RESEARCH (2023)

添加到收藏夹

Correction Cardiac & Cardiovascular Systems

efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies) (vol 10, 2045894020942121, 2020)

Hossein-Ardeschir Ghofrani, Ekkehard Grunig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier, Marc Humbert

PULMONARY CIRCULATION (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.